Stocks
Arcturus Therapeutics Holdings Financial Statements (ARCT) |
||||||||||
| Arcturus Therapeutics Holdingssmart-lab.ru | % | 2023Q4 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 31.12.2023 | 14.03.2024 | 08.05.2024 | 05.08.2024 | 07.11.2024 | 07.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 34.0 | 28.2 | 32.6 | 46.0 | 41.7 | 148.5 | |||
| Operating Income, bln rub | -15.1 | -11.1 | -30.4 | -2.68 | -10.7 | -54.9 | ||||
| EBITDA, bln rub | ? | -15.1 | -7.49 | -25.5 | -16.5 | -9.83 | -59.3 | |||
| Net profit, bln rub | ? | -8.57 | -8.57 | -26.8 | -17.2 | -6.90 | -59.5 | |||
| OCF, bln rub | ? | -0.545 | -5.56 | -29.8 | -24.1 | -60.0 | ||||
| CAPEX, bln rub | ? | 0.837 | 0.240 | 0.323 | 0.563 | 1.96 | ||||
| FCF, bln rub | ? | -1.38 | -5.80 | -30.2 | -23.5 | -60.8 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 49.1 | 38.5 | 63.0 | 47.8 | 49.6 | 198.8 | ||||
| Cost of production, bln rub | 0.000 | 0.815 | 5.41 | 0.900 | 0.000 | 7.13 | ||||
| R&D, bln rub | 36.6 | 26.8 | 53.6 | 36.3 | 39.1 | 155.9 | ||||
| Interest expenses, bln rub | 0.000 | 0.004 | 0.000 | 0.000 | 0.000 | 0.004 | ||||
| Assets, bln rub | 429.4 | 429.4 | 418.8 | 388.6 | 370.7 | 370.7 | ||||
| Net Assets, bln rub | ? | 281.6 | 278.5 | 264.0 | 258.6 | 261.9 | 261.9 | |||
| Debt, bln rub | 25.9 | 30.2 | 31.9 | 30.9 | 26.0 | 26.0 | ||||
| Cash, bln rub | 347.0 | 347.0 | 288.4 | 315.3 | 237.2 | 237.2 | ||||
| Net debt, bln rub | -321.1 | -316.8 | -256.5 | -284.4 | -211.2 | -211.2 | ||||
| Ordinary share price, rub | 31.5 | 31.5 | 33.8 | 24.4 | 23.2 | 19.0 | ||||
| Number of ordinary shares, mln | 26.6 | 26.6 | 26.9 | 27.0 | 27.1 | 27.1 | ||||
| Market cap, bln rub | 840 | 840 | 908 | 657 | 628 | 514 | ||||
| EV, bln rub | ? | 518 | 523 | 651 | 372 | 417 | 302 | |||
| Book value, bln rub | 282 | 279 | 264 | 259 | 262 | 262 | ||||
| EPS, rub | ? | -0.32 | -0.32 | -1.00 | -0.64 | -0.26 | -2.20 | |||
| FCF/share, rub | 0.00 | -0.05 | -0.22 | -1.12 | -0.87 | -2.25 | ||||
| BV/share, rub | 10.6 | 10.5 | 9.82 | 9.59 | 9.68 | 9.68 | ||||
| EBITDA margin, % | ? | -44.5% | -26.6% | -78.4% | -35.8% | -23.6% | -40.0% | |||
| Net margin, % | ? | -25.2% | -30.4% | -82.3% | -37.4% | -16.6% | -40.1% | |||
| FCF yield, % | ? | -2.32% | -2.49% | 1.09% | -10.8% | -9.69% | -11.8% | |||
| ROE, % | ? | -9.44% | -9.55% | -39.5% | -26.6% | -22.7% | -22.7% | |||
| ROA, % | ? | -6.19% | -6.19% | -24.9% | -17.7% | -16.1% | -16.1% | |||
| P/E | ? | -31.6 | -31.6 | -8.71 | -9.54 | -10.6 | -8.63 | |||
| P/FCF | -43.1 | -40.2 | 91.8 | -9.28 | -10.3 | -8.44 | ||||
| P/S | ? | 5.04 | 5.22 | 7.98 | 4.37 | 4.23 | 3.46 | |||
| P/BV | ? | 2.98 | 3.01 | 3.44 | 2.54 | 2.40 | 1.96 | |||
| EV/EBITDA | ? | -4.95 | -5.67 | -6.58 | -5.81 | -7.03 | -5.10 | |||
| Debt/EBITDA | 3.07 | 3.43 | 2.59 | 4.44 | 3.56 | 3.56 | ||||
| R&D/CAPEX, % | 3 204% | 22 322% | 11 239% | 6 947% | 7 937% | |||||
| CAPEX/Revenue, % | 0.00% | 2.97% | 0.74% | 0.70% | 1.35% | 1.32% | ||||
| Arcturus Therapeutics Holdings shareholders | ||||||||||
